YAYu.S. Artemenko

Yu.S. Artemenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu.S. Artemenko has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endometriosis: progestogen therapy. What’s new?

    by M.B. Khamoshina, D.S. Novginov, M.S. Tulupova, Yu.S. Artemenko, V.A. Ryabova

    Эндометриоз: терапия прогестагенами. Что нового?

  • Open Access

    Abnormal uterine bleeding in obesity in the reproductive period as a manifestation of the universal hypoxic syndrome

    by M.B. Khamoshina, M.R. Orazov, Yu.S. Artemenko, M.M. Azova, L.V. Tskhovrebova, A.V. Aghajanyan, I.A. Mullina

    Аномальные маточные кровотечения при ожирении в репродуктивном периоде как проявление универсального гипоксического синдрома

  • Open Access

    Hysteroscopic picture of recurrent endometrial hyperplasia without atypia in women of reproductive age

    by V.E. Radzinsky, M.R. Orazov, L.M. Mikhaleva, M.B. Khamoshina, I.A. Mullina, Yu.S. Artemenko

    Гистероскопическая картина рецидивирующей эндометриальной гиперплазии без атипии у женщин репродуктивного возраста


  • Open Access

    Metabesity: pathogenetic bases and predictive capabilities. A review

    by Mekan R. Orazov, Viktor E. Radzinsky, Marina B. Khamoshina, Evgeny D. Dolgov, Irina A. Mullina, Yulia S. Artemenko, Valentina A. Ryabova

    One of the most pressing problems of our time is obesity, recognized by the WHO as a pandemic of the XXI century. It is important to remember that obesity is a full-fledged nosological entity, but many women think that obesity is just a problem of beauty and aesthetics. It is important to note that this nosology has a number of serious consequences, starting with the development of cardiovascular disease and ending with cancer. However, the “problem in the problem” is the so-called “metabesity” – a new term that reflects a number of diseases, the pathogenesis of which is based on the metabolic syndrome. Obesity, metabolic syndrome and metabesity seem to be different concepts, but the absolute identity of the pathogenetic basis characterizes them as successive stages of one global process. In this regard, it is necessary to highlight the key mechanisms of the development of the described disorders and to consider the concept of clinical management of patients in this cohort.

  • Open Access

    Abnormal uterine bleeding in obese patients and polymorphisms of the eNOS, VEGF-A and HIF-1A genes

    by M.B. Khamoshina, Yu.S. Artemenko, M.M. Azova, L.V. Tskhovrebova, A.V. Aghajanyan, S.A. Petrovskaya

    Аномальные маточные кровотечения у пациенток с ожирением и полиморфизм генов eNOS, VEGF-A и HIF-1A


  • Open Access

    Metabesity in Women: Long-term Health Effects

    by M.R. Orazov, Peoples’ Friendship University of Russia, V.E. Radzinsky, M.B. Khamoshina, I.A. Mullina, Yu.S. Artemenko, V.A. Ryabova, Moscow 6 Miklouho-Maclay Str.

    Objective of the Review: To present the available data on the impact of obesity on woman’s health and quality of life. Key Points. The term “metabesity” includes a range of conditions associated with obesity and its sequelae. From pathogenic point of view, it is an obesity-associated metabolic aberration: subacute inflammation, mitochondrial dysfunction, and changed gut microbiome. Together with a genetic component, the phenotypes of metabesity are mostly a result of sedentary lifestyle and unhealthy eating. Metabesity is associated with a number of both health- and life-threatening comorbidities, including arterial hypertension, cardiac failure, myocardial infraction, and stroke. Insulin resistance, hypertensive disease, advanced arteriosclerosis, dyslipidemia and fatty hepatosis are more frequent in obese people than in the general population. This literature overview presents a modern idea of the metabesity impact on the long-term health of a woman. Conclusion. Recently, forecasting and prevention of diseases affecting the quality and duration of life have been attracting more and more interest. Taking into account the regular changes in the gender component of the population with age, obesity and its impact on the health of women from various age categories are of special interest. Obesity increases the risk and overall cancer mortality. Metabesity affects hormonal homoeostasis in the female body and increases the risk of degenerative conditions, including dementia. Taking into account the genetic component, the strategies to tackle metabesity, including a campaign against sedentary lifestyle and unhealthy eating, should be initiated since early childhood. Lifestyle modification is the only proven way to manage/prevent metabesity and associated diseases. Keywords: metabesity, obesity, metabolic syndrome, female health, cancer, diabetes, insulin resistance.


  • Pathomorphological features of endometrium in abnormal uterine bleeding in obese patients of reproductive age

    by Yu.S. Artemenko, M.B. Khamoshina, N.V. Petrenko, O.A. Demina, Moscow City Clinical Hospital Named V.M. Buyanov

    Патоморфологические особенности эндометрия при аномальных маточных кровотечениях у пациенток репродуктивного возраста с ожирением


  • Proliferative gynecological diseases and vitamin D deficiency: a look at the problem

    by M.B. Khamoshina, E.M. Dmitrieva, I.S. Zhuravleva, Yu.S. Artemenko, M.G. Lebedeva

    Недостаточность витамина D и -3 жирных кислот при пролиферативных гинекологических заболеваниях: взгляд на проблему

  • Open Access

    Polycystic ovary syndrome and obesity: a modern paradigm

    by Marina B. Khamoshina, Yulia S. Artemenko, Ayshan A. Bayramova, Valentina A. Ryabova, Mekan R. Orazov

    Polycystic ovary syndrome is a heterogeneous endocrine disease that affects women of childbearing age. The pathogenesis of polycystic ovary syndrome has not been fully studied to date, its paradigm considers the genetic determinism of the manifestation of hormonal and metabolic disorders, which are considered to be criteria for the verification of the disease (hyperandrogenism, oligo/anovulation and/or polycystic ovarian transformation during ultrasound examination (ultrasound). This review discusses the main ways of interaction between hyperandrogenism, insulin resistance and obesity and their role in the pathogenesis of polycystic ovary syndrome, as well as possible methods of treatment for this category of patients. The review analyzes the role of hyperandrogenism and insulin resistance in the implementation of the genetic scenario of polycystic ovary syndrome and finds out the reasons why women with polycystic ovary syndrome often demonstrate the presence of a «metabolic trio» - hyperinsulinemia, insulin resistance and type 2 diabetes mellitus. It is noted that obesity is not included in the criteria for the diagnosis of polycystic ovary syndrome, but epidemiological data confirm the existence of a relationship between these diseases. Obesity, especially visceral, which is often found in women with polycystic ovary syndrome, enhances and worsens metabolic and reproductive outcomes with polycystic ovary syndrome, as well as increases insulin resistance and compensatory hyperinsulinemia, which, in turn, stimulates adipogenesis and suppresses lipolysis. Obesity increases the sensitivity of tech cells to luteinizing hormone stimulation and enhances functional hyperandrogenism of the ovaries, increasing the production of androgens by the ovaries. Excess body weight is associated with a large number of inflammatory adipokines, which, in turn, contribute to the growth of insulin resistance and adipogenesis. Obesity and insulin resistance exacerbate the symptoms of hyperandrogenism, forming a vicious circle that contributes to the development of polycystic ovary syndrome. These data allow us to conclude that bariatric surgery can become an alternative to drugs (metformin, thiazolidinedione analogs of glucagon-like peptide-1), which has shown positive results in the treatment of patients with polycystic ovary syndrome and obesity.


  • Open Access

    Obesity in women: current aspects of reproductive health disorders

    by Yu. S. Artemenko, M. B. Khamoshina, V. A. Ryabova, Z. V. Zyukina

    Obesity and overweight tend to increase in prevalence in the whole world. Obese people have a higher incidence of cardiovascular diseases, stroke, osteoarthritis, diabetes mellitus and reproductive system diseases. This is especially evident in women. Hormonal imbalances is developed among obese women in the hypothalamic-pituitary-ovarian axis, typically there are menstruation disorders, anovulation and female infertility. Adipose tissue is an endocrine organ, with an intricate role in bioactive molecules secrete, in particularly adipokines, which interact differently with a variety of molecular pathways, contribute to the development of insulin resistance, inflammation, hypertension, increased risk of cardiovascular events, disorders of blood clotting, differentiation and maturation of oocytes. In addition, women with obesity and metabolic syndrome have problems with conception at the endometrial level often, a significantly higher risk of having a miscarriage, and worse assisted reproductive technology outcomes. Obesity has negative effects on the endometrium in non-pregnant women, it is increasing the risk of abnormal uterine bleeding. Hormones derived from adipose tissue could be affected on the function of the uterus/endometrium and, consequently, affect the amount of menstrual blood loss. Contradictory results are observed in patients with endometriosis. The correlation of body mass index to the risk of endometriosis has not been proven in clinical studies, but there was a direct relationship between the severity of endometriosis and a high body mass index. The review presents possible relationships of diseases of the reproductive system with obesity and overweight, determining their development and pathogenesis of disorders of the formation of the functions of reproductive organs.